GLP-1 Compounding Restrictions Tighten as FDA Resolves Shortages
With Semaglutide and Tirzepatide off the FDA shortage list, compounding pharmacies face new restrictions. Here's what changes for research-grade access.
The FDA has officially resolved the Semaglutide and Tirzepatide shortages on its national drug-shortage list. As a result, compounding pharmacies producing copies of these drugs face significantly tighter restrictions under section 503A and 503B of the Federal Food, Drug, and Cosmetic Act.
What changed
When a drug is on the FDA shortage list, compounding pharmacies are permitted to produce essentially equivalent versions to fill the gap. With Semaglutide and Tirzepatide off the shortage list as of early 2025:
- 503A compounders may no longer produce "essentially a copy" of these drugs unless a documented clinical difference justifies it (e.g., a different dosage form or excipient).
- 503B outsourcing facilities face similar limitations.
- Litigation is expected from compounding pharmacy networks, but enforcement actions have already begun.
What this means for research supply
The research-grade peptide market is distinct from the compounding pharmacy market — research peptides are sold for laboratory use, not as medicines, and the regulatory framework is different. However, the broader supply chain often overlaps:
- Research-grade Semaglutide and Tirzepatide remain available from peptide vendors marketing for laboratory use.
- Pricing for both has stabilized in early 2025 after the 2023–2024 supply shock.
- Some smaller vendors that entered the market during the shortage are exiting; this is expected to compress the vendor count over the next 12 months.
What to watch
- Enforcement actions against named compounders — these may set precedent.
- The FDA's formal shortage list — periodically re-evaluated.
- New GLP-1 agonists in late-stage trials (CagriSema, retatrutide) that may produce new shortages and re-open compounding under section 503A.
Practical takeaway
For researchers, this is a stability moment. Supply is back, prices are stable, and quality vendors with COA-per-batch (see our vendor checklist) are the most reliable picks.